ArcticZymes Technologies ASA (OSL:AZT)
Norway · Delayed Price · Currency is NOK | Market Cap | 1.05B -29.9% |
| Revenue (ttm) | 133.41M +27.9% |
| Net Income | 15.40M +449.4% |
| EPS | 0.31 +465.1% |
| Shares Out | 51.07M |
| PE Ratio | 67.36 |
| Forward PE | 49.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,420 |
| Open | 21.90 |
| Previous Close | 20.80 |
| Day's Range | 20.50 - 21.90 |
| 52-Week Range | 18.30 - 31.40 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About OSL:AZT
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of... [Read more]
Financial Performance
In 2025, OSL:AZT's revenue was 118.21 million, an increase of 9.34% compared to the previous year's 108.11 million. Earnings were 9.74 million, an increase of 14.97%.
Financial StatementsNews
ArcticZymes Technologies ASA Earnings Call Transcript: Q2 2026
Q2 2026 saw 19% revenue growth and a doubling of EBITDA, driven by strong performance in both Molecular Tools and Biomanufacturing, despite currency headwinds. Strategic milestones included onboarding a new CDMO and a customer’s FDA approval, supporting a positive outlook for sustained growth.
ArcticZymes Technologies ASA Quarterly report: Q2 2026
ArcticZymes Technologies ASA has published its Q2 2026 quarterly earnings report on August 14, 2026.
ArcticZymes Technologies ASA Slides: Q2 2026
ArcticZymes Technologies ASA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
ArcticZymes Technologies ASA Earnings Call Transcript: Q1 2026
Q1 saw 41% revenue growth and a return to profitability, driven by strong molecular tools and biomanufacturing segments. Strategic milestones included a new RNA enzyme patent and expanded partnerships, with a robust outlook for continued growth and diversification.
ArcticZymes Technologies ASA Slides: Q1 2026
ArcticZymes Technologies ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
ArcticZymes Technologies ASA Quarterly report: Q1 2026
ArcticZymes Technologies ASA has published its Q1 2026 quarterly earnings report on May 7, 2026.
ArcticZymes Technologies ASA Transcript: CMD 2026
The company is executing a strategy to scale its enzyme platform through diversification, innovation, and customer-centric solutions, targeting high-growth markets like metagenomics and RNA therapeutics. Strong financials, validated customer impact, and a focus on operational leverage underpin ambitions for double-digit growth and market outperformance.
ArcticZymes Technologies ASA Press release: FY 2026
ArcticZymes Technologies ASA issued a press release on March 6, 2026, disclosing material business information to investors.
ArcticZymes Technologies ASA Slides: FY 2026
ArcticZymes Technologies ASA has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 6, 2026.
ArcticZymes Technologies ASA Earnings Call Transcript: Q4 2025
Q4 and full year 2025 delivered strong revenue and EBITDA growth, driven by commercial transformation, product portfolio expansion, and strategic partnerships. Biomanufacturing and molecular tools segments both showed robust performance, with momentum expected to continue into 2026.
ArcticZymes Technologies ASA Quarterly report: Q4 2025
ArcticZymes Technologies ASA has published its Q4 2025 quarterly earnings report on February 12, 2026.
ArcticZymes Technologies ASA Slides: Q4 2025
ArcticZymes Technologies ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
ArcticZymes Technologies ASA Annual report: Q4 2025
ArcticZymes Technologies ASA has published its Q4 2025 annual report on February 12, 2026.
ArcticZymes Technologies ASA Earnings Call Transcript: Q3 2025
Q3 saw 24% revenue growth and a return to profitability, driven by strong molecular tools and biomanufacturing performance. A major European partnership and robust cash position set the stage for long-term growth, with new applications and markets fueling future expansion.
ArcticZymes Technologies ASA Quarterly report: Q3 2025
ArcticZymes Technologies ASA has published its Q3 2025 quarterly earnings report on November 6, 2025.
ArcticZymes Technologies ASA Slides: Q3 2025
ArcticZymes Technologies ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
ArcticZymes Technologies ASA Slides: Pareto Securities Healthcare Conference Presentation
ArcticZymes Technologies ASA has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2025.